IN8bio develops next-generation cellular therapies for cancer treatment and has seen significant growth in its immuno-oncology programs, including activated and gene-modified adoptive cellular therapies designed to protect cells from chemotherapy and may allow for new combinations of drugs to disrupt the tumor microenvironment and increase immunogenicity. To support research and development collaboration, In8Bio needed to consolidate its scientific operations in one location with access to additional space to expand research activities. Located within the historic Martin Biscuit Building, a two-story, 53,800 SF commercial building built in 1928, EwingCole designed the new BSL-2 biotechnology lab to support clinical-stage therapies for cancer treatments that employ allogeneic, autologous, and genetically modified gamma-delta T cells. Critical to the research and development operations, the renovation right-sizes the R&D spaces, equipment, and utilities within tenant spaces, increases efficiency by improving functional adjacencies of R&D operations with the office and support spaces, and optimizes personnel and material flow. The facility includes culture and research areas, new rooftop equipment and supporting steel structure, system upgrades, and office and administrative support areas.